X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OCU400 is an NR2E3 modulator, subretinally administered cell and gene therapy drug candidate, which is currently being evaluated for the treatment of retinitis pigmentosa.
Lead Product(s): OCU400
Therapeutic Area: Genetic Disease Product Name: OCU400
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (ROR Related Orphan Receptor A) gene. It is being studied for the treatment of geographic atrophy.
Lead Product(s): OCU410
Therapeutic Area: Ophthalmology Product Name: OCU410
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
OCU410ST (AAV5-hRORA) is a modifier gene therapy candidate, which utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. It is being evaluated for the treatment of patients with Stargardt Disease.
Lead Product(s): AAV5-hRORA
Therapeutic Area: Genetic Disease Product Name: OCU410ST
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
OCU410 is a potential curative single sub-retinal injection which is under development for geographic atrophy secondary to dry age-related macular degeneration. OCU410 utilizes an AAV delivery platform for the retinal delivery of the RAR Related Orphan Receptor A gene.
Lead Product(s): OCU410
Therapeutic Area: Ophthalmology Product Name: OCU410
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
OCU410ST (AAV5-hRORA) is a modifier gene therapy candidate, which utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. It is being evaluated for the treatment of patients with Stargardt Disease.
Lead Product(s): AAV5-hRORA
Therapeutic Area: Genetic Disease Product Name: OCU410ST
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Ocugen investigational product candidate OCU400, which is an NR2E3 gene Transference. It is being evaluated in the Phase I/II clinical trial studies in patients with RHO and other gene mutations associated with Retinitis Pigmentosa.
Lead Product(s): OCU400
Therapeutic Area: Genetic Disease Product Name: OCU400
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
OCU400 is an AAV based gene therapy candidate which is under phase 1/2 clinical development for the treatment of Retinitis Pigmentosa associated with RHO mutations & Leber congenital amaurosis (LCA).
Lead Product(s): OCU400
Therapeutic Area: Genetic Disease Product Name: OCU400
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
OCU410 is a potential curative single sub-retinal injection which is under development for geographic atrophy secondary to dry age-related macular degeneration. OCU410 utilizes an AAV delivery platform for the retinal delivery of the RAR Related Orphan Receptor A gene.
Lead Product(s): OCU410
Therapeutic Area: Ophthalmology Product Name: OCU410
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the retina, often resulting in slow progressive vision loss in children and adults.
Lead Product(s): OCU410ST
Therapeutic Area: Genetic Disease Product Name: OCU410ST
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
OCU500 is a mucosal vaccine candidate which is delivered via two different mucosal routes, inhalation into the lungs and as a nasal spray, which is investigated for the treatment of COVID-19 and influenza (flu).
Lead Product(s): OCU500
Therapeutic Area: Infections and Infectious Diseases Product Name: OCU500
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
